Table 3:
Summary of clients’ characteristics by injectable opioid agonist treatment program, with national-level tallies
| Program | Total no. of client starts; scan | No. of active clients;* scan | No. on wait list; scan | Age, yr, mean (range) | No. of clients; scan; gender | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | |||||||||||||
|
|
|
|
|
|
||||||||||
| Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | F | M | T† | F | M | T† | |
| A–D: All PHS programs‡§ | 286 | 312 | 67 | 119 | 0 | 112 | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ |
|
| ||||||||||||||
| tHDM | – | 60 | ||||||||||||
|
| ||||||||||||||
| E: St. Paul’s Hospital‡ | ‡ | ‡ | 8 | 8 | 0 | 0 | ‡ | ‡ | 2 | 6 | 0 | 2 | 6 | 0 |
|
| ||||||||||||||
| F: Crosstown Clinic | 259 | 291 | 126 | 125 | 345 | 400 | 44 (21–69) | 44 (21–69) | 31 | 94 | 1 | 39 | 85 | 1 |
|
| ||||||||||||||
| DAM | 106 | 107 | ||||||||||||
|
| ||||||||||||||
| G: Vancouver Native Health Clinic | 10 | – | 1 | – | 0 | – | 53 (53) | – | 0 | 1 | 0 | – | – | – |
|
| ||||||||||||||
| H: Downtown Community Health Centre | 7 | 18 | 4 | 11 | 0 | 0 | 51 (36–68) | 48 (36–68) | 1 | 3 | 0 | 4 | 7 | 0 |
|
| ||||||||||||||
| I: Lookout iOAT Clinic | 37 | 77 | 22 | 18 | 0 | 0 | 45 (30–61) | 44 (27–62) | 4 | 18 | 0 | 4 | 14 | 0 |
|
| ||||||||||||||
| J–L: All Ottawa Inner City Health programs‡ | 26 | 29 | 22 | 22 | ≥ 55 | ≥ 75 | 40 (25–57) | 43 (25–57) | 11 | 11 | 0 | 12 | 10 | 0 |
|
| ||||||||||||||
| M: Sheldon M. Chumir Health Centre | – | 45 | – | 22 | – | 0 | – | 35 (22–48) | – | – | – | 4 | 18 | 0 |
|
| ||||||||||||||
| N: Royal Alexandra Hospital | – | 9 | – | 6 | – | 0 | – | 44 (29–64) | – | – | – | 3 | 3 | 0 |
|
| ||||||||||||||
| National-level tallies | 625 | 781 | 250 | 331 | ≥ 400 | ≥ 587 | 47 (21–69) | 43 (21–69) | 49 | 133 | 1 | 68 | 143 | 1 |
Note: DAM = diacetylmorphine, F= female, iOAT = injectable opioid agonist treatment, M = male, T = transgender or nonbinary, tHDM = tablet hydromorphone.
Clients receiving at least 1 dose of iOAT in the 7 days before the scan reference date. All numbers represent clients receiving liquid hydromorphone except where programs provided DAM or tHDM (tablet iOAT) in addition to liquid hydromorphone; in these cases, the number of active clients receiving DAM and tHDM is reported underneath the total number of active clients, to indicate the size of these specific client groups.
There was variable reporting for this gender category across sites.
Data not available or data stratified by program not available where more than 1 program was operated by a single organization.
Age and gender data available only at follow-up for the 312 client starts: mean age 41 (20–73) yr, 230 men (74%), 77 women (25%), 5 transgender or nonbinary people (2%).